Combating pancreatic cancer with ovarian cancer cells

Xiao Lin, Chunmei Cui, Qinghua Cui

TL;DR

This paper proposes a novel "combat cancer with cancer" (CCC) therapeutic strategy for pancreatic cancer (PC) by using ovarian cancer cells (SKOV3) to inhibit PC growth. This approach, validated in vitro and in vivo, appears to work by modulating pancreas-specific gene expression rather than through immune pathways, suggesting a new therapeutic avenue.

What Problem Does This Paper Address?

Pancreatic cancer (PC) is notoriously lethal, with a five-year survival rate below 10%. Current treatments, including surgery, chemotherapy, and radiation, are often ineffective, especially in advanced stages. The incidence of PC is also rising, making it a critical unmet medical need. Existing immunotherapies have shown limited success in solid tumors like PC, highlighting the urgent need for novel therapeutic strategies.

Methods

The researchers employed a multi-pronged approach:

  • Reverse-transcriptomics and DrugMine: They used a computational tool called DrugMine to identify potential therapeutic agents by searching for gene expression signatures that are anti-correlated with PC. This is a standard approach for drug discovery.
  • In vitro Co-culture: Ovarian cancer cells (SKOV3) were co-cultured with pancreatic cancer cells (SW1990) to assess their direct impact on cancer cell proliferation.
  • Animal Xenograft Model: Subcutaneous xenografts of SW1990 cells were established in mice, and then treated with SKOV3 cells (both wild-type and genetically engineered) to evaluate therapeutic efficacy in vivo.
  • RNA-sequencing: This technique was used to analyze gene expression changes in tumors treated with SKOV3 cells compared to control tumors. This is a standard method for understanding molecular mechanisms.
  • Functional and Pathway Analysis (DAVID, WEAT): These tools were used to interpret the RNA-seq data, identifying enriched biological processes, pathways, and diseases associated with the observed gene expression changes.
  • Genetic Engineering: SKOV3 cells were engineered to express the African elephant's TP53 gene to investigate if this modification could enhance therapeutic effects.

Datasets

  • GEO accession number: GSE56560: Gene expression profiles of 28 PDAC specimens and 2 normal pancreatic tissues were used for initial screening.
  • GEO accession number: GSE212173: RNA-sequencing data from pancreatic cancer xenografts with and without SKOV3 treatment were made publicly available.

Key Insights and Ideas

  • Ovarian Cancer as a "Drug": The most striking insight is the identification of ovarian serous carcinoma as a top candidate agent predicted to reverse PC gene signatures. This "combat cancer with cancer" (CCC) concept is novel.
  • Pancreas-Specific Modulation: The RNA-seq analysis revealed that SKOV3 treatment primarily affects genes involved in pancreas function, regeneration, and cell adhesion, rather than immune or inflammatory pathways. This suggests a mechanism distinct from traditional immunotherapy.
  • TP53 Enhancement: Incorporating the African elephant's TP53 gene into SKOV3 cells significantly boosted their inhibitory effect on pancreatic tumors, highlighting the potential of genetically engineered CCC therapeutics.
  • Blocking EMT: The analysis pointed to the epithelial-mesenchymal transition (EMT) pathway as a potential target, suggesting that ovarian cancer cells might inhibit PC metastasis.

Key Results

  • In vitro Inhibition: SKOV3 cells significantly inhibited SW1990 cell proliferation by approximately 37% in co-culture experiments.
  • In vivo Tumor Growth Inhibition: In animal models, SKOV3 cell injection significantly reduced pancreatic tumor weight and volume compared to the control group.
  • Enhanced Efficacy with TP53: SKOV3 cells engineered with the African elephant TP53 gene showed enhanced tumor inhibition compared to wild-type SKOV3 cells.
  • No Immune Modulation: Functional analysis indicated that the therapeutic effect was not mediated by immune or inflammation-related pathways.
  • Gene Expression Reversal: The gene expression changes induced by SKOV3 treatment were found to be anti-correlated with the gene expression signature of pancreatic cancer.

Limitations and Future Work

  • Clinical Feasibility of Intratumoral Injection: The paper acknowledges that the feasibility of intratumoral injection in clinical practice needs further exploration. Surgery with cell transplantation is suggested as an alternative.
  • Dose Optimization: Only two doses of injected cells were tested in animal experiments; further exploration is needed to optimize dosage for better efficacy.
  • Mechanism Elucidation: While key pathways like EMT are implicated, the exact molecular mechanisms of CCC therapeutics require deeper investigation.
  • Survival Data: The current study focused on tumor weight and volume; future work should include survival time analysis.
  • Broader Cell Line Testing: The study used only one ovarian cancer cell line (SKOV3) and one pancreatic cancer cell line (SW1990). Testing a wider range of cell lines is crucial for validation.
  • Generalizability: The authors suggest that this CCC approach might be applicable to other cancers, which warrants further investigation.
  • Drug Discovery Potential: The identification of drug-related connections to DEGs opens avenues for exploring existing drugs or developing new ones for PC treatment.

Summary updated

Abstract

With overall five-year survival rate less than 10%, pancreatic cancer (PC) represents the most lethal one in all human cancers. Given that the incidence of PC is still increasing and current cancer treatment strategies are often inefficacious, its therapy is still a huge challenge. Here, we first revealed ovarian serous carcinoma is mostly anti-correlated with pancreatic cancer in gene expression signatures. Based on this observation, we proposed that ovarian cancer cells could defend PC. To confirm this strategy, we first showed that ovarian cancer cell SKOV3 can significantly inhibit the proliferation of pancreatic cancer cell SW1990 when they were co-cultured. We further validated this strategy by an animal model of pancreatic cancer xenografts. The result showed that the injection of SKOV3 significantly inhibits pancreatic cancer xenografts. Moreover, we found that SKOV3 with transgenic African elephant <i>TP53</i> gene further enhances the therapeutic effect. RNA-sequencing analysis revealed that the ovarian cancer cell treatment strikingly induced changes of genes being involved in pancreas function and phenotype (e.g. enhancing pancreas function, pancreas regeneration, and cell adhesion) but not immune and inflammation-related functions, suggesting that the proposed strategy is different from immunotherapy and could be a novel strategy for cancer treatment.
BibTeX
@inproceedings{lin2023combating,
  author = {Xiao Lin and Chunmei Cui and Qinghua Cui},
  title = {{Combating pancreatic cancer with ovarian cancer cells}},
  booktitle = {Aging},
  year = {2023},
  doi = {10.18632/aging.204608},
}
Figure